ETF Evaluator:
iShares Genomics Immnlgy & Hlthcr ETF (IDNA)
Follow This ETF
(as of Jul 31)
Best Performing in Health Over the Last Year
| 177.8% | Virtus LifeSci Biotech Clinical Trls ETF (BBC) |
| 114.6% | ALPS Medical Breakthroughs ETF (SBIO) |
| 91.7% | State Street® SPDR® S&P® Biotech ETF (XBI) |
| 83.9% | F/m Emerald Life Sciences Innovation ETF (LFSC) |
| 79.5% | iShares Neuroscience and Healthcare ETF (IBRN) |
Risk
Index
Risk
Index
ETF Details
iShares Genomics Immnlgy & Hlthcr ETF Overview
iShares Genomics Immnlgy & Hlthcr ETF (IDNA) is a passively managed Sector Equity Health exchange-traded fund (ETF). iShares launched the ETF in 2019.
The investment seeks to track the investment results of the NYSE® FactSet® Global Genomics and Immuno Biopharma IndexTM.
The fund generally will invest at least 80% of its assets in the component securities of the index and in investments that have economic characteristics that are substantially identical to the component securities of the index and may invest up to 20% of its assets in certain futures, options and swap contracts, cash and cash equivalents. The index is composed of developed and emerging market companies that could benefit from the long-term growth and innovation in genomics, immunology and bioengineering. -null-. The fund is non-diversified.
About iShares Genomics Immnlgy & Hlthcr ETF (IDNA)
There are 4 members of the management team with an average tenure of 2.70 years: Jennifer Hsui (2019), Peter Sietsema (2025), Matt Waldron (2025) and Steven White (2025). Management tenure is more important for actively managed ETFs than passive index ETFs.
The ETF has 2 primary benchmarks: MSCI ACWI NR USD index with a weighting of 100% and NYSE FactSet Glb Gnmcs&Imm Bio NR USD index with a weighting of 100%. iShares Genomics Immnlgy & Hlthcr ETF has 69 securities in its portfolio. The top 10 holdings constitute 42.0% of the ETF’s assets. The ETF meets the SEC requirement of being classified as a nondiversified fund. The ETF is not considered to have an ESG focus with its investment selection and management.
iShares Genomics Immnlgy & Hlthcr ETF is part of the Equity global asset class and is within the Sector Equity ETF group. iShares Genomics Immnlgy & Hlthcr ETF has 34.6% of its portfolio invested in foreign issues. The overall assets allocated to domestic stock is 65.1% There is 34.6% allocated to foreign stock, and 0.0% is allocated to preferred stocks. The bond allocation as a percentage of total assets is 0.0% (0.0% domestic bond, 0.0% foreign bond and 0.0% convertible bond). iShares Genomics Immnlgy & Hlthcr ETF has 0.3% of the portfolio in cash.
Assets Under Management
The fund has $193 million in total assets, which is below the $1 billion average for the Health category. Normally, lower assets under management translates to higher average expense ratios, and greater total assets are desired. However, for some investment categories, such as small-cap investing, it may be difficult for the manager to fully employ the desired active strategy if assets grow too large or too quickly.
IDNA Performance and Fees
The expense ratio measures how much of a fund’s assets are used for administrative expenses and operating expenses, including adviser fees and fees for the transfer agent and custodial services. The iShares Genomics Immnlgy & Hlthcr ETF expense ratio is average compared to funds in the Health category. iShares Genomics Immnlgy & Hlthcr ETF has an expense ratio of 0.47%, which is 9% lower than its category average, making the fund expense ratio grade a C. While it is difficult to predict returns, it is known that high annual expense ratios reduce your rate of return, and excessive fees are difficult to overcome. Active management normally comes with higher expense ratios than passive index management. Certain investment categories such as small company and foreign also normally have higher expense ratios. It is best to compare fund expense ratios against the category averages for meaningful assessments.
High portfolio turnover can translate to higher expenses and lower aftertax returns. iShares Genomics Immnlgy & Hlthcr ETF has a portfolio turnover rate of 49%, which indicates that it holds its assets around / 0.0 years. By way of comparison, the average portfolio turnover is 40% for the Health category.
Recently, in the month of June 2026, iShares Genomics Immnlgy & Hlthcr ETF returned 12.9%, which earned it a grade of B, as the Health category had an average return of 8.7%. The letter grades of A, B, C, D and F are based upon relative rankings within the investment category. A grade of A, for example, would indicate that the return is in the highest 20% for that time period compared to all ETFs in that category.
iShares Genomics Immnlgy & Hlthcr ETF has a trailing yield of 0.83%, which is below the 1.12% category average.
The fund normally distributes its income semi-annually.
It’s natural to seek the best-performing investments, but you must consider the relationship between risk and return and the impact of costs and taxes on your realized returns.
iShares Genomics Immnlgy & Hlthcr ETF Grades
Year to date, the ETF has returned 29.1%, 19.0 percentage points better than the category, which translates into a grade of A. The fund has returned 65.5% over the past year (grade of A), 14.3% over the past three years (grade of B) and -7.4% per year over the past five years (grade of F).
For more ETF grades, analysis and screening tools to help your investment discovery, join AAII for a $2, full-access trial. Learn more here: https://invest.aaii.com/membership.
Otherwise, for more information about iShares Genomics Immnlgy & Hlthcr ETF, including its riskiness, submit your email to unlock the rest of the article.
Gain access to exclusive AAII member-only content.
IDNA Trailing NAV Total Returns Data as of 6/30/26
| Last Month |
Last Quarter |
Ann'l. 1Yr |
Ann'l. 3Yr |
Ann'l. 5Yr |
Ann'l. 10Yr |
|
| IDNA Return (NAV) | 12.9% | 17.0% | 65.5% | 14.3% | -7.4% | na |
| IDNA Return (Price) | 13.4% | 16.7% | 66.2% | 14.4% | -7.4% | na |
| NAV +/- Price Return | -0.498% | 0.375% | -0.745% | -0.069% | -0.024% | na |
| Health Avg | 8.7% | 13.9% | 37.6% | 10.6% | 1.5% | 9.5% |
| IDNA Grade (NAV) | B | B | A | B | F | na |
| +/- Category (NAV) | 4.2% | 3.1% | 27.9% | 3.7% | -8.9% | na |
| IDNA Tax-Cost Ratio | na | na | 0.3% | 0.3% | 0.3% | na |
IDNA Annual NAV Total ReturnsData as of 6/30/26
| 2026 | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | |
| IDNA Return (NAV) | 29.1% | 17.4% | -1.0% | -7.8% | -42.1% | -4.0% | 54.5% | na | na | na | na |
| IDNA Return (Price) | 29.4% | 17.3% | -0.7% | -7.6% | -42.3% | -4.0% | 54.3% | na | na | na | na |
| NAV +/- Price Ret | 0.010% | -0.006% | -0.266% | -0.019% | 0.004% | -0.005% | -0.004% | na | na | na | na |
| Health Avg | 10.1% | 21.8% | 0.1% | 2.2% | -16.3% | 4.3% | 30.5% | 25.4% | -1.5% | 26.5% | -10.2% |
| IDNA Grade (NAV) | A | D | D | F | F | D | A | na | na | na | na |
| +/- Category | 19.0% | -4.4% | -1.1% | -10.0% | -25.8% | -8.3% | 24.0% | na | na | na | na |
| Risk Measures | |
| Beta: | 1.10 |
| R-Squared: | 36% |
| Standard Deviation: | 23.1% |
| Category Risk Index: | 1.15 |
| Category Risk Rating: | High |
| Total Risk Index: | 1.90 |
| Total Risk Rating: | High |
| Portfolio Characteristics | |
| Yield: | 0.8% |
| Total Assets: | $ 194 Mil |
| Share Class Assets: | $ 194 Mil |
| Turnover: | 49.0% |
| Expense Ratio: | 0.47% |
| Index Fund: | Yes |
| Index Tracked: | MSCI ACWI NR USD |
| Index Weighting: | 100% |
| Leveraged: | No |
| Socially Responsible Fund: | No |
| Capital Gains Distribution Frequency: | |
| Income Distribution Frequency: | Semi-Annually |
Management Team
| Number of Managers: 4 | |||
| Longest Tenure: 7.1 years | |||
| Average Tenure: 2.7 years | |||
| Managers (Year): Hsui Jennifer (2019), Sietsema Peter (2025), Waldron Matt (2025), White Steven (2025) | |||
Portfolio Composition (as of 6/30/26)
| # of Holdings: | 69 |
| % in Top 10 Holdings: | 42.0% |
| Fund is Non-Diversified: | Yes |
| % in Foreign Issues: | 34.6% |
Portfolio Allocation |
|
| Domestic Stock: | 65.1% |
| Foreign Stock: | 34.6% |
| Preferred Stock: | 0.0% |
| Domestic Bond: | 0.0% |
| Foreign Bond: | 0.0% |
| Convertible Bond: | 0.0% |
| Other: | 0.0% |
| Cash: | 0.3% |
Purchase Information
| Legal Structure: | Open Ended Investment Company |
| Fund Family: | iShares |
| Phone Number: | 800-474-2737 |
| Website: | au.ishares.com |
| Inception Date: | June 11, 2019 |
Expenses and Fees
| Expense Ratio (%): | 0.47% (Rating: Avg) |
| Category Average Expense Ratio (%): | 0.52% |
